

Indications for Lowering LDL Cholesterol in Rheumatoid Arthritis: An Unrecognized Problem

MARTIN SOUBRIER, DJAMILA ZERKAK, and MAXIME DOUGADOS

ABSTRACT. *Objectives.* To evaluate the prevalence of patients with rheumatoid arthritis (RA) in whom lowering low density lipoprotein cholesterol (LDL-C) should be considered in accord with the ATPIII guidelines. The treatment goals are based on the number of risk factors (RF) other than LDL-C. The goal for 0–1 RF is < 160 mg/l, for multiple RF < 130 mg/l, and < 100 mg/l for coronary heart disease (CHD) or CHD risk equivalent (other clinical atherosclerotic diseases and diabetes mellitus).

Methods. A cross-sectional study was conducted in 145 patients with RA. We recorded the patients' characteristics, the potential risk factors for CHD, and results of lipid profile tests [total cholesterol (TC), high density lipoprotein cholesterol, and LDL-C].

Results. Of the 145 patients recruited, 23 had LDL-C lowering therapy. Of the remaining 122 patients (mean age 54 ± 15 years), of whom 101 (83%) were women, 109 were taking a disease modifying antirheumatic drug. At the time of the study, disease duration was 12 ± 10 years. Twenty-seven (22%) of the 122 patients needed lowering of LDL-C. If RA was considered as an additional risk factor or a major risk factor, like diabetes mellitus, 35 patients (29%) and 86 (70%) patients, respectively, needed lowering therapy.

Conclusion. Our study shows the high percentage of patients with RA for whom LDL-C intervention should be considered. As cardiovascular morbidity and mortality is increased in patients with RA, it would be useful to determine whether RA should be considered as an independent cardiovascular risk factor or as a major risk factor like diabetes that warrants more aggressive cardiac prevention measures. (First release July 15 2006; J Rheumatol 2006;33:1766–9)

Key Indexing Terms:

RHEUMATOID ARTHRITIS CARDIOVASCULAR DISEASE ATHEROSCLEROSIS STATINS

In patients with established rheumatoid arthritis (RA) mortality is higher than that in the general population and cardiovascular disease is the most common cause of death^{1–3}. There is also documented evidence of increased incidence of non-fatal cardiovascular events in RA^{4–8}. This increased cardiovascular risk could be caused by the increased prevalence of classical risk factors for cardiovascular disease in RA patients such as dyslipidemia, diabetes mellitus or insulin resistance, hypertension and smoking habits, by the underlying inflammatory process of RA itself, by the effects of disease modifying antirheumatic drugs (DMARD) or corticosteroids, or because of undertreatment of cardiovascular comorbidity¹. In this study we focused on the management of hypercholesterolemia in RA patients.

The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII) has issued recommendations on the optimal

low density lipoprotein-cholesterol (LDL-C) value according to the patient's overall cardiovascular risk factor profile⁹.

We conducted a cross-sectional analysis of a referral cohort of French patients with RA to determine the prevalence of patients for whom lowering of LDL-C should be considered in accord with the ATPIII recommendations.

MATERIALS AND METHODS

We conducted a prospective monocentric study in Cochin Hospital, Paris, a tertiary-care center with a large RA population, between January and April 2004. We asked consent from 220 consecutive patients fulfilling the American College of Rheumatology (ACR) criteria for RA to perform a lipid profile, and 145 agreed.

Treatment goals for LDL-C were set according to the number of risk factors. The positive risk factors are: age (male ≥ 45 yrs, female ≥ 55 yrs); family history of premature coronary heart disease (CHD; definite myocardial infarction or sudden death before 55 years of age in father or other male first-degree relative, or before 65 years of age in mother or other female first-degree relative); current cigarette smoking; hypertension ($\geq 140/90$ or anti-hypertensive medication); and low high-density lipoprotein cholesterol (HDL-C; < 40 mg/dl). A high HDL-C level (≥ 60 mg/dl) is a protective risk factor. The guidelines recommend that in patients without CHD the goal for 0–1 risk factors (RF) is < 160 mg/l, for multiple RF < 130 mg/l, and < 100mg/l for multiple RF with a CHD risk > 20% per 10 years. The goal in patients with CHD or CHD risk equivalent (other clinical atherosclerotic diseases, diabetes mellitus) is < 100 mg/dl.

Data collection

Cardiovascular disease. All patients were asked about any history of cardiovascular disease, cardiovascular risk factors (personal and family history of

From Service de Rhumatologie, Hôpital G. Montpied, Clermont-Ferrand; and Université René Descartes, AP-HP Hôpital Cochin, Paris, France.

M. Soubrier, MD, PhD, Service de Rhumatologie, Hôpital G. Montpied; D. Zerkak, MD; M. Dougados, MD, Université René Descartes, AP-HP Hôpital Cochin.

Address reprint requests to Dr. M. Soubrier, Service de rhumatologie, Hôpital G. Montpied, Place H. Dunant, B.P. 69, 63003 Clermont-Ferrand, France. E-mail: msoubrier@chu-clermontferrand.fr

Accepted for publication April 27, 2006.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2006. All rights reserved.

cardiovascular events, current cigarette smoking, hypertension, and diabetes), and use of lipid-lowering drugs. Arterial blood pressure and body mass index were recorded.

Assessment of RA. A thorough survey of all patients' records from disease onset was performed including disease duration, actual and previous DMARD, and total and daily dose of corticosteroids. Disease activity was evaluated in each patient using the following indices: tender and swollen joint count (28 j), morning stiffness, visual analog scale (VAS) for pain (0-10), patient's and doctor's global assessment, Westergren erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). We used the Disease Activity Score (DAS28) based on ESR or CRP to assess disease activity (26). A DAS28 > 5.1 means high disease activity, < 3.2 low disease activity, and 3.2-5.1 moderate disease activity.

Total cholesterol (TC) and HDL-C determinations. Plasma lipids were determined after 12 h overnight fast. TC, HDL-C, and triglycerides were measured and LDL-C was calculated by the method of Friedewald, *et al*¹⁰.

Statistics. All results were expressed as means (SD). Comparison between groups was done by chi-square test. A p value < 0.05 (two tailed) was considered significant.

RESULTS

Clinical and demographic characteristics of study population. One hundred forty-five patients (116 women, 29 men) were enrolled for the study. Twenty-three patients were receiving LDL-C lowering therapy (20 on statins) and 8 had had myocardial infarction. Of the 122 remaining patients, most had longstanding (mean disease duration 12 yrs) seropositive (74%) and erosive (88%) RA (Table 1). One hundred nine patients (89%) were taking a DMARD: 46 (38%) were taking anti-tumor necrosis factor (TNF), 19 methotrexate, 14 combination leflunomide-methotrexate, 8 leflunomide, 5 hydroxy-

chloroquine, and the remaining 17 different DMARD combinations including 9 with hydroxychloroquine. Eighty-four percent were taking corticosteroids. The mean DAS28(ESR) was 3.95 and the mean DAS28(CRP) was 3.7. According to the DAS28(CRP) criteria, 47 patients had low disease activity, 54 moderate disease activity, and 21 high disease activity.

In the 122 patients, the mean cholesterol values were: TC, 220 ± 47 mg/dl; HDL-C 69 ± 22 mg/dl; LDL-C 129 ± 41 mg/dl. Atherogenic index (TC/HDL-C) was 3.55 ± 1.7.

Two patients had had previous myocardial infarction and 3 had diabetes mellitus. One patient had 3 risk factors, 25 had 2 risk factors, 53 one risk factor, and 38 no risk factors (Table 2). According to ATPIII guidelines, 27 patients (22%) needed LDL-C-lowering therapy. If RA is considered an additional risk factor, 35 patients (29%) should have been receiving primary prevention. If RA is considered a strong risk factor for cardiovascular disease, similar to diabetes mellitus, 86 patients (70%) should have been receiving primary prevention. On the basis of disease activity, 5 patients with high disease activity, 12 with moderate disease activity, and 11 with low disease activity (p = 0.98) should have been receiving primary prevention and 7, 17, and 12, respectively, if RA is considered an additional risk factor (p = 0.74).

DISCUSSION

Despite an inordinately high risk of cardiovascular events in RA, assessment of cardiovascular risks was uncommon in our practice and cholesterol-lowering treatment was insufficiently prescribed. The precise reasons for the observed increase in cardiovascular disease-related morbidity and mortality in RA patients remain to be established. The prevalence of traditional cardiovascular disease risk factors (smoking, diabetes mellitus, hypertension, dyslipidemia, family history) has not been consistently documented in this population. Thus, traditional risk factors were examined in a cross-sectional study of women with and without RA who were enrolled in the Nurses' Health Study¹¹. No significant differences between these groups were observed for current smoking status, body mass index, menopause status, diabetes, hypertension, and family history of early myocardial infarction. However, an unfavorable lipid profile, i.e., decreased HDL-C and/or increased atherogenic index, has been documented in active RA^{12,13}. The lipid profile usually returns to normal when control of the joint disease is achieved^{12,14}, but DMARD may alter lipid levels. Antimalarials improve the lipid profiles by increasing

Table 1. Characteristics of the 122 patients.

| | No. (%) of Patients, mean ± SD |
|--------------------------------------|--------------------------------|
| Demographics | |
| Age, yrs | 54 ± 14 |
| Female, no. (%) | 101 (83) |
| Disease duration, yrs | 12 ± 10 |
| Positive RF, no. (%) | 90 (74) |
| Bony erosions (%) | 106 (87) |
| No. of previous DMARD | 4.1 ± 2.1 |
| Concomitant treatment | |
| Corticosteroids, no. (%) | 103 (84) |
| Corticosteroid dose, mg/day | 4.5 ± 3.7 |
| TNF-α blockers | 46 (38) |
| Disease characteristics | |
| Tender joint count | 3.7 ± 4.7 |
| Swollen joint count | 5.5 ± 4.6 |
| VAS for pain | 3.8 ± 2.8 |
| Patient's global assessment (0-10) | 4 ± 2.8 |
| Physician's global assessment (0-10) | 3.6 ± 2.3 |
| ESR, mm/h | 25 ± 20 |
| CRP, mg/l | 14 ± 18 |
| DAS 28 (VS) | 3.97 ± 1.43 |
| DAS 28 (CRP) | 3.69 ± 1.29 |

RF: risk factors; DMARD: disease modifying antirheumatic drugs; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.

Table 2. Cardiovascular risk factors.

| Risk Factor | No. (%) of Patients |
|---|---------------------|
| Age (male > 45 yrs, female > 55 yrs) | 64 (52) |
| Family history | 9 (7) |
| Tobacco use | 21 (17) |
| Hypertension or antihypertensive medication | 28 (23) |
| HDL cholesterol < 40 mg/dl | 9 (7) |

HDL-C levels and decreasing those of LDL-C¹⁵. The effects of TNF- α antagonists on lipid profile are controversial¹⁶⁻¹⁸.

RA itself is an independent risk factor for developing cardiovascular disease. Del Rincon, *et al* compared the incidence of fatal and nonfatal myocardial infarctions and ischemic strokes in 236 patients with RA and 4635 controls participating in an epidemiological study (age 25-65 yrs, mean followup 8 yrs and 33,881 patient-yrs)⁶. After adjustment for cardiovascular risk factors (age, sex, smoking history, diabetes, hypercholesterolemia, and systolic blood pressure), the relative risk for cardiovascular events was 3.17 (95% CI 1.33-6.36) in the patients with RA. In the prospective Nurses' Health Study, 114,342 women aged 30 to 55 years and free of cardiovascular disease and RA in 1976 were followed up until 1996⁷. After 2.4 million patient-years of followup, the relative risk for cardiovascular events in the 527 patients who experienced onset of RA was 2 (95% CI 1.23-3.29) after adjustment for cardiovascular risk factors. In patients with RA for longer than 10 years, the relative risk of myocardial infarction was 3.1 (95% CI 1.64-5.87). Accumulating evidence suggests that atherosclerosis and cardiovascular disease are truly inflammatory disorders¹⁹. Overlapping pathogenic features of the 2 diseases include T cell activation, the predominant role of proinflammatory cytokines (TNF- α , interleukin 6) with elevated serum levels of acute-phase reactant¹⁹. Epidemiological studies in general populations have established that higher CRP levels predict cardiovascular events²⁰⁻²³. Because CRP and LDL-C reflect different risk factors, determining both variables may improve cardiovascular risk detection²⁰. Thus, the inflammatory syndrome that characterizes RA may lead to early atheroma.

Hydroxymethylglutaryl-coenzyme A reductase inhibitors reduce cardiovascular morbidity and mortality and are widely used in primary and secondary prevention of vascular disease. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) trial was important because it showed that LDL-lowering statin therapy in persons with only borderline-high LDL-C levels and few other risk factors produces a large reduction in relative risk (-37% in major coronary events and -33% in revascularization procedures)²⁴. While there is no evidence specifically in patients with RA that controlling dyslipemia according to current recommendations reduces cardiovascular disease, there is no reason to believe that benefits would not occur. The beneficial effect of statins as primary or secondary prevention is not entirely ascribable to a cholesterol-lowering effect. Statins exert antiinflammatory effects, decreasing CRP production by 15% to 25%²⁵. Patients who experience decreases in both LDL-C and CRP during statin therapy have a lower risk of recurrent myocardial infarction²⁶ and greater decreases in plaque burden as measured by intracoronary ultrasound²⁷. They are therefore potentially ideal drugs to target CHD risk in RA, which is associated with inflammation. Furthermore, atorvastatin has clinically apparent antiinflammatory effects in active RA²⁸.

The goals to aim for in LDL-C treatment depend on the number of cardiovascular risk factors. We have shown that if traditional cardiovascular risk factors alone are taken into account too many patients miss out on cholesterol-lowering treatment. Given the elevated risk of CHD in RA, we think RA itself should be considered as an extra risk factor. Were this the case, there would be wider prescription of cholesterol-lowering drugs. The decision to initiate treatment could also be taken by multiplying overall cardiovascular risk as assessed by existing charts by 1.7 or 2 to derive a more accurate level of risk in RA patients²⁹. The question also arises whether RA should be considered a major risk factor, like diabetes mellitus, requiring more aggressive cardiac prevention.

Our conclusion is that cholesterol-lowering therapy is insufficiently prescribed in our patients with RA. As the lipid profile changes with disease activity, serial lipid determination should be performed. Our results highlight the need for all physicians to screen appropriately for cardiovascular risk factors and to treat all rheumatoid patients with abnormal lipid values.

REFERENCES

1. Van Doormun S, McColl G, Wicks IP. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? *Arthritis Rheum* 2002;46:862-73.
2. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. *Arthritis Rheum* 1994;37:481-94.
3. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. *J Rheumatol* 2003;30:1196-202.
4. Wolfe F, Freundlich B, Strauss WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. *J Rheumatol* 2003;30:36-40.
5. Tureson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. *Ann Rheum Dis* 2004;63:952-55.
6. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. *Arthritis Rheum* 2001;44:2737-45.
7. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* 2003;107:1303-7.
8. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. *Arthritis Rheum* 2005;52:402-11.
9. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. *Circulation* 2002;106:388-91.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. *Clin Chem* 1972; 18:499-502.
11. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. *Arthritis Rheum* 2004;50:3444-9.
12. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of

- glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. *Ann Rheum Dis* 2003;62:842-5.
13. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. *J Rheumatol* 1999;26:1701-4.
 14. Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. *Am J Med* 2002;113:188-93.
 15. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. *Ann Rheum Dis* 1997; 56:374-7.
 16. Gauza E, Gauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti-TNF- α antibody therapy leads to elevated triglyceride and reduced LDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. *Wien Klin Wochenschr* 2002;114:1004-7.
 17. Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. *J Rheumatol* 2005;32:252-5.
 18. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. *Ann Rheum Dis* 2005;64:303-5.
 19. Pasceri V, Yeh ETH. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. *Circulation* 1999;100:2124-6.
 20. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. *Circulation* 2004;109[Suppl 1]:II2-10.
 21. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of the first cardiovascular events. *N Engl J Med* 2002;347:1557-65.
 22. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004;350:1387-97.
 23. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. *N Engl J Med* 2004;351:2599-610.
 24. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998; 279:1615-22.
 25. Halcox JP, Deanfield JE. Beyond the laboratory. Clinical implications for statin pleiotropy. *Circulation* 2004;109[Suppl 1]:II42-8.
 26. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med* 2005;352:20-8.
 27. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary disease. *N Engl J Med* 2005;352:29-38.
 28. McCarey D, McInnes I, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double blind, randomized placebo-controlled trial. *Lancet* 2004;363:2015-21.
 29. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. *Curr Opin Rheumatol* 2005;17:286-92.